Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.

Drug Dev Res 2014 Nov;75 Suppl 1:S27-30

Department of Dermatology, University of Rome "Tor Vergata", Rome, 00133, Italy.

Overexpression of tumor necrosis factor alpha (TNF-α) has been demonstrated to play a pivotal role in the pathogenesis of both plaque-type psoriasis and psoriatic arthritis. TNF-α blockers, including etanercept, a human protein that acts as a TNF-α soluble receptor, are effective in the treatment of psoriasis. This retrospective study investigated the impact of psoriasis patients' demographic and clinical characteristics on primary inefficacy to etanercept. Our findings suggest that the presence of psoriatic arthritis is a risk factor for primary inefficacy to etanercept in the treatment of psoriasis. However, etanercept efficacy appears to be independent of patient age, gender, or previous biologic treatments.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ddr.21206DOI Listing
November 2014
18 Reads

Publication Analysis

Top Keywords

primary inefficacy
12
inefficacy etanercept
8
retrospective study
8
psoriatic arthritis
8
treatment psoriasis
8
etanercept
5
etanercept human
4
arthritis tnf-α
4
findings presence
4
including etanercept
4
etanercept efficacy
4
blockers including
4
tnf-α blockers
4
psoriasis
4
etanercept findings
4
pivotal role
4
appears independent
4
role pathogenesis
4
efficacy appears
4
plaque-type psoriasis
4

Similar Publications